You are here

Allergan bets on rising popularity of botox for men

Move is part of firm's strategy to go after smaller markets in traditional pharmaceutical industry

New York

FINE lines. Double chins. Sagging skin. Allergan Plc is betting that these byproducts of ageing are becoming an obsession for men.

After completing a deal valued at US$70.5 billion to buy the maker of Botox injections, Allergan announced on Wednesday that it would pay US$2